U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C25H31NO6
Molecular Weight 441.5177
Optical Activity UNSPECIFIED
Defined Stereocenters 8 / 8
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DEFLAZACORT

SMILES

CC1=N[C@]2(C(=O)COC(=O)C)[C@@]([H])(C[C@@]3([H])[C@]4([H])CCC5=CC(=O)C=C[C@]5(C)[C@@]4([H])[C@]([H])(C[C@@]32C)O)O1

InChI

InChIKey=FBHSPRKOSMHSIF-GRMWVWQJSA-N
InChI=1S/C25H31NO6/c1-13-26-25(20(30)12-31-14(2)27)21(32-13)10-18-17-6-5-15-9-16(28)7-8-23(15,3)22(17)19(29)11-24(18,25)4/h7-9,17-19,21-22,29H,5-6,10-12H2,1-4H3/t17-,18-,19-,21+,22+,23-,24-,25+/m0/s1

HIDE SMILES / InChI

Molecular Formula C25H31NO6
Molecular Weight 441.5177
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 7 / 8
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment:: description was created based on several sources, including, http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2763756/

Deflazacort is a glucocorticoid developed for the treatment of different inflammatory and immune conditions. The drug is rapidly metabolized to an active metabolite, 21-hydroxy-deflazaxort that may cross the blood brain barrier. Deflazacort acts by suppressing inflammatory response.

CNS Activity

Sources: www.ncbi.nlm.nih.gov/pubmed/10229911
Curator's Comment:: Deflazacort active metabolite, 21-hydroxy-deflazacort crosses the blood-brain barrier in very low concentrations.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
CALCORT

Approved Use

Treat inflammation including asthma, arthritis and allergies; treat problems with skin, kidney, heart, digestive system, eyes or blood, treat problems where body has growths (tumours), suppress the immune system in transplant operations.
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
381 ng/mL
0.9 mg/kg single, oral
dose: 0.9 mg/kg
route of administration: Oral
experiment type: SINGLE
co-administered:
21-DESACETYLDEFLAZACORT plasma
Homo sapiens
population: UNHEALTHY
age: ADOLESCENT
sex: UNKNOWN
food status: UNKNOWN
206 ng/mL
0.9 mg/kg single, oral
dose: 0.9 mg/kg
route of administration: Oral
experiment type: SINGLE
co-administered:
21-DESACETYLDEFLAZACORT plasma
Homo sapiens
population: UNHEALTHY
age: CHILD
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
655 ng × h/mL
0.9 mg/kg single, oral
dose: 0.9 mg/kg
route of administration: Oral
experiment type: SINGLE
co-administered:
21-DESACETYLDEFLAZACORT plasma
Homo sapiens
population: UNHEALTHY
age: ADOLESCENT
sex: UNKNOWN
food status: UNKNOWN
400 ng × h/mL
0.9 mg/kg single, oral
dose: 0.9 mg/kg
route of administration: Oral
experiment type: SINGLE
co-administered:
21-DESACETYLDEFLAZACORT plasma
Homo sapiens
population: UNHEALTHY
age: CHILD
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
60%
0.9 mg/kg single, oral
dose: 0.9 mg/kg
route of administration: Oral
experiment type: SINGLE
co-administered:
21-DESACETYLDEFLAZACORT plasma
Homo sapiens
population: UNHEALTHY
age: ADOLESCENT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
1.2 mg/kg 1 times / day multiple, oral
Higher than recommended
Dose: 1.2 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 1.2 mg/kg, 1 times / day
Sources: Page: 6.1
unhealthy, 5 - 15 years
Health Status: unhealthy
Condition: Duchenne muscular dystrophy
Age Group: 5 - 15 years
Sex: unknown
Sources: Page: 6.1
Other AEs: Cushingoid, Erythema...
Other AEs:
Cushingoid (69%)
Erythema (49%)
Hirsutism (37%)
Headache (34%)
Weight increased (32%)
Constipation (15%)
Abdominal pain upper (14%)
Skin striae (11%)
Acne (11%)
Abdominal discomfort (8%)
Sources: Page: 6.1
0.9 mg/kg 1 times / day multiple, oral
Recommended
Dose: 0.9 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.9 mg/kg, 1 times / day
Sources: Page: Table 1
unhealthy, 5 - 15 years
n = 51
Health Status: unhealthy
Condition: Duchenne muscular dystrophy
Age Group: 5 - 15 years
Sex: unknown
Population Size: 51
Sources: Page: Table 1
Other AEs: Cushingoid, Weight increased...
Other AEs:
Cushingoid (33%)
Weight increased (20%)
Increased appetite (14%)
Upper respiratory tract infection (12%)
Cough (12%)
Pollakiuria (12%)
Nasopharyngitis (10%)
Hirsutism (10%)
Central obesity (10%)
Erythema (8%)
Irritability (8%)
Rhinorrhea (8%)
Abdominal discomfort (6%)
Sources: Page: Table 1
0.9 mg/kg 1 times / day multiple, oral
Recommended
Dose: 0.9 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.9 mg/kg, 1 times / day
Sources: Page: Table 1
unhealthy, 5 - 15 years
n = 51
Health Status: unhealthy
Condition: Duchenne muscular dystrophy
Age Group: 5 - 15 years
Sex: unknown
Population Size: 51
Sources: Page: Table 1
Other AEs: Cushingoid, Hirsutism...
Other AEs:
Cushingoid (60%)
Hirsutism (35%)
Weight increased (28%)
Erythema (28%)
Central obesity (25%)
Abdominal pain (18%)
Pollakiuria (15%)
Constipation (10%)
Irritability (10%)
Abnormal behavior (9%)
Pyrexia (9%)
Back pain (7%)
Rash (7%)
Contusion (6%)
Nausea (6%)
Psychomotor hyperactivity (6%)
Epistaxis (6%)
Skin striae (6%)
Sources: Page: Table 1
AEs

AEs

AESignificanceDosePopulation
Acne 11%
1.2 mg/kg 1 times / day multiple, oral
Higher than recommended
Dose: 1.2 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 1.2 mg/kg, 1 times / day
Sources: Page: 6.1
unhealthy, 5 - 15 years
Health Status: unhealthy
Condition: Duchenne muscular dystrophy
Age Group: 5 - 15 years
Sex: unknown
Sources: Page: 6.1
Skin striae 11%
1.2 mg/kg 1 times / day multiple, oral
Higher than recommended
Dose: 1.2 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 1.2 mg/kg, 1 times / day
Sources: Page: 6.1
unhealthy, 5 - 15 years
Health Status: unhealthy
Condition: Duchenne muscular dystrophy
Age Group: 5 - 15 years
Sex: unknown
Sources: Page: 6.1
Abdominal pain upper 14%
1.2 mg/kg 1 times / day multiple, oral
Higher than recommended
Dose: 1.2 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 1.2 mg/kg, 1 times / day
Sources: Page: 6.1
unhealthy, 5 - 15 years
Health Status: unhealthy
Condition: Duchenne muscular dystrophy
Age Group: 5 - 15 years
Sex: unknown
Sources: Page: 6.1
Constipation 15%
1.2 mg/kg 1 times / day multiple, oral
Higher than recommended
Dose: 1.2 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 1.2 mg/kg, 1 times / day
Sources: Page: 6.1
unhealthy, 5 - 15 years
Health Status: unhealthy
Condition: Duchenne muscular dystrophy
Age Group: 5 - 15 years
Sex: unknown
Sources: Page: 6.1
Weight increased 32%
1.2 mg/kg 1 times / day multiple, oral
Higher than recommended
Dose: 1.2 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 1.2 mg/kg, 1 times / day
Sources: Page: 6.1
unhealthy, 5 - 15 years
Health Status: unhealthy
Condition: Duchenne muscular dystrophy
Age Group: 5 - 15 years
Sex: unknown
Sources: Page: 6.1
Headache 34%
1.2 mg/kg 1 times / day multiple, oral
Higher than recommended
Dose: 1.2 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 1.2 mg/kg, 1 times / day
Sources: Page: 6.1
unhealthy, 5 - 15 years
Health Status: unhealthy
Condition: Duchenne muscular dystrophy
Age Group: 5 - 15 years
Sex: unknown
Sources: Page: 6.1
Hirsutism 37%
1.2 mg/kg 1 times / day multiple, oral
Higher than recommended
Dose: 1.2 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 1.2 mg/kg, 1 times / day
Sources: Page: 6.1
unhealthy, 5 - 15 years
Health Status: unhealthy
Condition: Duchenne muscular dystrophy
Age Group: 5 - 15 years
Sex: unknown
Sources: Page: 6.1
Erythema 49%
1.2 mg/kg 1 times / day multiple, oral
Higher than recommended
Dose: 1.2 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 1.2 mg/kg, 1 times / day
Sources: Page: 6.1
unhealthy, 5 - 15 years
Health Status: unhealthy
Condition: Duchenne muscular dystrophy
Age Group: 5 - 15 years
Sex: unknown
Sources: Page: 6.1
Cushingoid 69%
1.2 mg/kg 1 times / day multiple, oral
Higher than recommended
Dose: 1.2 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 1.2 mg/kg, 1 times / day
Sources: Page: 6.1
unhealthy, 5 - 15 years
Health Status: unhealthy
Condition: Duchenne muscular dystrophy
Age Group: 5 - 15 years
Sex: unknown
Sources: Page: 6.1
Abdominal discomfort 8%
1.2 mg/kg 1 times / day multiple, oral
Higher than recommended
Dose: 1.2 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 1.2 mg/kg, 1 times / day
Sources: Page: 6.1
unhealthy, 5 - 15 years
Health Status: unhealthy
Condition: Duchenne muscular dystrophy
Age Group: 5 - 15 years
Sex: unknown
Sources: Page: 6.1
Central obesity 10%
0.9 mg/kg 1 times / day multiple, oral
Recommended
Dose: 0.9 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.9 mg/kg, 1 times / day
Sources: Page: Table 1
unhealthy, 5 - 15 years
n = 51
Health Status: unhealthy
Condition: Duchenne muscular dystrophy
Age Group: 5 - 15 years
Sex: unknown
Population Size: 51
Sources: Page: Table 1
Hirsutism 10%
0.9 mg/kg 1 times / day multiple, oral
Recommended
Dose: 0.9 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.9 mg/kg, 1 times / day
Sources: Page: Table 1
unhealthy, 5 - 15 years
n = 51
Health Status: unhealthy
Condition: Duchenne muscular dystrophy
Age Group: 5 - 15 years
Sex: unknown
Population Size: 51
Sources: Page: Table 1
Nasopharyngitis 10%
0.9 mg/kg 1 times / day multiple, oral
Recommended
Dose: 0.9 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.9 mg/kg, 1 times / day
Sources: Page: Table 1
unhealthy, 5 - 15 years
n = 51
Health Status: unhealthy
Condition: Duchenne muscular dystrophy
Age Group: 5 - 15 years
Sex: unknown
Population Size: 51
Sources: Page: Table 1
Cough 12%
0.9 mg/kg 1 times / day multiple, oral
Recommended
Dose: 0.9 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.9 mg/kg, 1 times / day
Sources: Page: Table 1
unhealthy, 5 - 15 years
n = 51
Health Status: unhealthy
Condition: Duchenne muscular dystrophy
Age Group: 5 - 15 years
Sex: unknown
Population Size: 51
Sources: Page: Table 1
Pollakiuria 12%
0.9 mg/kg 1 times / day multiple, oral
Recommended
Dose: 0.9 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.9 mg/kg, 1 times / day
Sources: Page: Table 1
unhealthy, 5 - 15 years
n = 51
Health Status: unhealthy
Condition: Duchenne muscular dystrophy
Age Group: 5 - 15 years
Sex: unknown
Population Size: 51
Sources: Page: Table 1
Upper respiratory tract infection 12%
0.9 mg/kg 1 times / day multiple, oral
Recommended
Dose: 0.9 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.9 mg/kg, 1 times / day
Sources: Page: Table 1
unhealthy, 5 - 15 years
n = 51
Health Status: unhealthy
Condition: Duchenne muscular dystrophy
Age Group: 5 - 15 years
Sex: unknown
Population Size: 51
Sources: Page: Table 1
Increased appetite 14%
0.9 mg/kg 1 times / day multiple, oral
Recommended
Dose: 0.9 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.9 mg/kg, 1 times / day
Sources: Page: Table 1
unhealthy, 5 - 15 years
n = 51
Health Status: unhealthy
Condition: Duchenne muscular dystrophy
Age Group: 5 - 15 years
Sex: unknown
Population Size: 51
Sources: Page: Table 1
Weight increased 20%
0.9 mg/kg 1 times / day multiple, oral
Recommended
Dose: 0.9 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.9 mg/kg, 1 times / day
Sources: Page: Table 1
unhealthy, 5 - 15 years
n = 51
Health Status: unhealthy
Condition: Duchenne muscular dystrophy
Age Group: 5 - 15 years
Sex: unknown
Population Size: 51
Sources: Page: Table 1
Cushingoid 33%
0.9 mg/kg 1 times / day multiple, oral
Recommended
Dose: 0.9 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.9 mg/kg, 1 times / day
Sources: Page: Table 1
unhealthy, 5 - 15 years
n = 51
Health Status: unhealthy
Condition: Duchenne muscular dystrophy
Age Group: 5 - 15 years
Sex: unknown
Population Size: 51
Sources: Page: Table 1
Abdominal discomfort 6%
0.9 mg/kg 1 times / day multiple, oral
Recommended
Dose: 0.9 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.9 mg/kg, 1 times / day
Sources: Page: Table 1
unhealthy, 5 - 15 years
n = 51
Health Status: unhealthy
Condition: Duchenne muscular dystrophy
Age Group: 5 - 15 years
Sex: unknown
Population Size: 51
Sources: Page: Table 1
Erythema 8%
0.9 mg/kg 1 times / day multiple, oral
Recommended
Dose: 0.9 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.9 mg/kg, 1 times / day
Sources: Page: Table 1
unhealthy, 5 - 15 years
n = 51
Health Status: unhealthy
Condition: Duchenne muscular dystrophy
Age Group: 5 - 15 years
Sex: unknown
Population Size: 51
Sources: Page: Table 1
Irritability 8%
0.9 mg/kg 1 times / day multiple, oral
Recommended
Dose: 0.9 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.9 mg/kg, 1 times / day
Sources: Page: Table 1
unhealthy, 5 - 15 years
n = 51
Health Status: unhealthy
Condition: Duchenne muscular dystrophy
Age Group: 5 - 15 years
Sex: unknown
Population Size: 51
Sources: Page: Table 1
Rhinorrhea 8%
0.9 mg/kg 1 times / day multiple, oral
Recommended
Dose: 0.9 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.9 mg/kg, 1 times / day
Sources: Page: Table 1
unhealthy, 5 - 15 years
n = 51
Health Status: unhealthy
Condition: Duchenne muscular dystrophy
Age Group: 5 - 15 years
Sex: unknown
Population Size: 51
Sources: Page: Table 1
Constipation 10%
0.9 mg/kg 1 times / day multiple, oral
Recommended
Dose: 0.9 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.9 mg/kg, 1 times / day
Sources: Page: Table 1
unhealthy, 5 - 15 years
n = 51
Health Status: unhealthy
Condition: Duchenne muscular dystrophy
Age Group: 5 - 15 years
Sex: unknown
Population Size: 51
Sources: Page: Table 1
Irritability 10%
0.9 mg/kg 1 times / day multiple, oral
Recommended
Dose: 0.9 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.9 mg/kg, 1 times / day
Sources: Page: Table 1
unhealthy, 5 - 15 years
n = 51
Health Status: unhealthy
Condition: Duchenne muscular dystrophy
Age Group: 5 - 15 years
Sex: unknown
Population Size: 51
Sources: Page: Table 1
Pollakiuria 15%
0.9 mg/kg 1 times / day multiple, oral
Recommended
Dose: 0.9 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.9 mg/kg, 1 times / day
Sources: Page: Table 1
unhealthy, 5 - 15 years
n = 51
Health Status: unhealthy
Condition: Duchenne muscular dystrophy
Age Group: 5 - 15 years
Sex: unknown
Population Size: 51
Sources: Page: Table 1
Abdominal pain 18%
0.9 mg/kg 1 times / day multiple, oral
Recommended
Dose: 0.9 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.9 mg/kg, 1 times / day
Sources: Page: Table 1
unhealthy, 5 - 15 years
n = 51
Health Status: unhealthy
Condition: Duchenne muscular dystrophy
Age Group: 5 - 15 years
Sex: unknown
Population Size: 51
Sources: Page: Table 1
Central obesity 25%
0.9 mg/kg 1 times / day multiple, oral
Recommended
Dose: 0.9 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.9 mg/kg, 1 times / day
Sources: Page: Table 1
unhealthy, 5 - 15 years
n = 51
Health Status: unhealthy
Condition: Duchenne muscular dystrophy
Age Group: 5 - 15 years
Sex: unknown
Population Size: 51
Sources: Page: Table 1
Erythema 28%
0.9 mg/kg 1 times / day multiple, oral
Recommended
Dose: 0.9 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.9 mg/kg, 1 times / day
Sources: Page: Table 1
unhealthy, 5 - 15 years
n = 51
Health Status: unhealthy
Condition: Duchenne muscular dystrophy
Age Group: 5 - 15 years
Sex: unknown
Population Size: 51
Sources: Page: Table 1
Weight increased 28%
0.9 mg/kg 1 times / day multiple, oral
Recommended
Dose: 0.9 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.9 mg/kg, 1 times / day
Sources: Page: Table 1
unhealthy, 5 - 15 years
n = 51
Health Status: unhealthy
Condition: Duchenne muscular dystrophy
Age Group: 5 - 15 years
Sex: unknown
Population Size: 51
Sources: Page: Table 1
Hirsutism 35%
0.9 mg/kg 1 times / day multiple, oral
Recommended
Dose: 0.9 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.9 mg/kg, 1 times / day
Sources: Page: Table 1
unhealthy, 5 - 15 years
n = 51
Health Status: unhealthy
Condition: Duchenne muscular dystrophy
Age Group: 5 - 15 years
Sex: unknown
Population Size: 51
Sources: Page: Table 1
Contusion 6%
0.9 mg/kg 1 times / day multiple, oral
Recommended
Dose: 0.9 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.9 mg/kg, 1 times / day
Sources: Page: Table 1
unhealthy, 5 - 15 years
n = 51
Health Status: unhealthy
Condition: Duchenne muscular dystrophy
Age Group: 5 - 15 years
Sex: unknown
Population Size: 51
Sources: Page: Table 1
Epistaxis 6%
0.9 mg/kg 1 times / day multiple, oral
Recommended
Dose: 0.9 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.9 mg/kg, 1 times / day
Sources: Page: Table 1
unhealthy, 5 - 15 years
n = 51
Health Status: unhealthy
Condition: Duchenne muscular dystrophy
Age Group: 5 - 15 years
Sex: unknown
Population Size: 51
Sources: Page: Table 1
Nausea 6%
0.9 mg/kg 1 times / day multiple, oral
Recommended
Dose: 0.9 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.9 mg/kg, 1 times / day
Sources: Page: Table 1
unhealthy, 5 - 15 years
n = 51
Health Status: unhealthy
Condition: Duchenne muscular dystrophy
Age Group: 5 - 15 years
Sex: unknown
Population Size: 51
Sources: Page: Table 1
Psychomotor hyperactivity 6%
0.9 mg/kg 1 times / day multiple, oral
Recommended
Dose: 0.9 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.9 mg/kg, 1 times / day
Sources: Page: Table 1
unhealthy, 5 - 15 years
n = 51
Health Status: unhealthy
Condition: Duchenne muscular dystrophy
Age Group: 5 - 15 years
Sex: unknown
Population Size: 51
Sources: Page: Table 1
Skin striae 6%
0.9 mg/kg 1 times / day multiple, oral
Recommended
Dose: 0.9 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.9 mg/kg, 1 times / day
Sources: Page: Table 1
unhealthy, 5 - 15 years
n = 51
Health Status: unhealthy
Condition: Duchenne muscular dystrophy
Age Group: 5 - 15 years
Sex: unknown
Population Size: 51
Sources: Page: Table 1
Cushingoid 60%
0.9 mg/kg 1 times / day multiple, oral
Recommended
Dose: 0.9 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.9 mg/kg, 1 times / day
Sources: Page: Table 1
unhealthy, 5 - 15 years
n = 51
Health Status: unhealthy
Condition: Duchenne muscular dystrophy
Age Group: 5 - 15 years
Sex: unknown
Population Size: 51
Sources: Page: Table 1
Back pain 7%
0.9 mg/kg 1 times / day multiple, oral
Recommended
Dose: 0.9 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.9 mg/kg, 1 times / day
Sources: Page: Table 1
unhealthy, 5 - 15 years
n = 51
Health Status: unhealthy
Condition: Duchenne muscular dystrophy
Age Group: 5 - 15 years
Sex: unknown
Population Size: 51
Sources: Page: Table 1
Rash 7%
0.9 mg/kg 1 times / day multiple, oral
Recommended
Dose: 0.9 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.9 mg/kg, 1 times / day
Sources: Page: Table 1
unhealthy, 5 - 15 years
n = 51
Health Status: unhealthy
Condition: Duchenne muscular dystrophy
Age Group: 5 - 15 years
Sex: unknown
Population Size: 51
Sources: Page: Table 1
Abnormal behavior 9%
0.9 mg/kg 1 times / day multiple, oral
Recommended
Dose: 0.9 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.9 mg/kg, 1 times / day
Sources: Page: Table 1
unhealthy, 5 - 15 years
n = 51
Health Status: unhealthy
Condition: Duchenne muscular dystrophy
Age Group: 5 - 15 years
Sex: unknown
Population Size: 51
Sources: Page: Table 1
Pyrexia 9%
0.9 mg/kg 1 times / day multiple, oral
Recommended
Dose: 0.9 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.9 mg/kg, 1 times / day
Sources: Page: Table 1
unhealthy, 5 - 15 years
n = 51
Health Status: unhealthy
Condition: Duchenne muscular dystrophy
Age Group: 5 - 15 years
Sex: unknown
Population Size: 51
Sources: Page: Table 1
OverviewDrug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
weak
weak
weak
weak
weak
weak
Drug as victimTox targets
PubMed

PubMed

TitleDatePubMed
Prednisone versus deflazacort in the treatment of autoimmune thrombocytopenic purpura: evaluation of clinical response and immunological modifications.
1991 Jul-Aug
Effectiveness of nifedipine and deflazacort in the management of distal ureter stones.
2000 Oct 1
Transactivation via the human glucocorticoid and mineralocorticoid receptor by therapeutically used steroids in CV-1 cells: a comparison of their glucocorticoid and mineralocorticoid properties.
2004 Sep
Patents

Patents

Sample Use Guides

The usual dose for most conditions, including rheumatoid arthritis is half to three tablets each day, the dose for severe asthma may be up to 8 or 12 tablets each day.
Route of Administration: Oral
In Vitro Use Guide
Phytohaemagglutinin stimulated peripheral blood lymphocytes, NK and K cells were incubated with different concentrations of the drug (0, 1.2, 6.0, 24, 60, 240, and 600 x 10(-7) M) and the immunosuppressive effect was measured. Deflazacort suppressed the cells in a dose dependent way.
Substance Class Chemical
Created
by admin
on Sat Jun 26 13:44:51 UTC 2021
Edited
by admin
on Sat Jun 26 13:44:51 UTC 2021
Record UNII
KR5YZ6AE4B
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
DEFLAZACORT
INN   MART.   MI   USAN   USP-RS   WHO-DD  
USAN   INN  
Official Name English
EMFLAZA
Brand Name English
DEFLAZACORT [WHO-DD]
Common Name English
DEFLAZACORT [USP-RS]
Common Name English
11.BETA.,21-DIHYDROXY-2'-METHYL-5'.BETA.H-PREGNA-1,4-DIENO(17,16-D)OXAZOLE-3,20-DIONE 21-ACETATE
Common Name English
DEFLAZACORT [MI]
Common Name English
MDL-458
Code English
DEFLAZACORT [USAN]
Common Name English
DEFLAZACORT [ORANGE BOOK]
Common Name English
MDL458
Code English
DEFLAZACORT [INN]
Common Name English
5'H-PREGNA-1,4-DIENO(17,16-D)OXAZOLE-3,20-DIONE, 21-(ACETYLOXY)-11-HYDROXY-2'-METHYL-, (11.BETA.,16.BETA.)-
Common Name English
DEFLAZACORT [MART.]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C521
Created by admin on Sat Jun 26 13:44:52 UTC 2021 , Edited by admin on Sat Jun 26 13:44:52 UTC 2021
FDA ORPHAN DRUG 491715
Created by admin on Sat Jun 26 13:44:52 UTC 2021 , Edited by admin on Sat Jun 26 13:44:52 UTC 2021
FDA ORPHAN DRUG 315110
Created by admin on Sat Jun 26 13:44:52 UTC 2021 , Edited by admin on Sat Jun 26 13:44:52 UTC 2021
WHO-VATC QH02AB13
Created by admin on Sat Jun 26 13:44:52 UTC 2021 , Edited by admin on Sat Jun 26 13:44:52 UTC 2021
FDA ORPHAN DRUG 403413
Created by admin on Sat Jun 26 13:44:52 UTC 2021 , Edited by admin on Sat Jun 26 13:44:52 UTC 2021
WHO-ATC H02AB13
Created by admin on Sat Jun 26 13:44:52 UTC 2021 , Edited by admin on Sat Jun 26 13:44:52 UTC 2021
NDF-RT N0000175576
Created by admin on Sat Jun 26 13:44:52 UTC 2021 , Edited by admin on Sat Jun 26 13:44:52 UTC 2021
Code System Code Type Description
USP_CATALOG
1166116
Created by admin on Sat Jun 26 13:44:52 UTC 2021 , Edited by admin on Sat Jun 26 13:44:52 UTC 2021
PRIMARY USP-RS
LACTMED
Deflazacort
Created by admin on Sat Jun 26 13:44:52 UTC 2021 , Edited by admin on Sat Jun 26 13:44:52 UTC 2021
PRIMARY
MERCK INDEX
M4135
Created by admin on Sat Jun 26 13:44:52 UTC 2021 , Edited by admin on Sat Jun 26 13:44:52 UTC 2021
PRIMARY Merck Index
EPA CompTox
14484-47-0
Created by admin on Sat Jun 26 13:44:52 UTC 2021 , Edited by admin on Sat Jun 26 13:44:52 UTC 2021
PRIMARY
ECHA (EC/EINECS)
238-483-7
Created by admin on Sat Jun 26 13:44:52 UTC 2021 , Edited by admin on Sat Jun 26 13:44:52 UTC 2021
PRIMARY
DRUG BANK
DB11921
Created by admin on Sat Jun 26 13:44:52 UTC 2021 , Edited by admin on Sat Jun 26 13:44:52 UTC 2021
PRIMARY
WIKIPEDIA
Deflazacort
Created by admin on Sat Jun 26 13:44:52 UTC 2021 , Edited by admin on Sat Jun 26 13:44:52 UTC 2021
PRIMARY
FDA UNII
KR5YZ6AE4B
Created by admin on Sat Jun 26 13:44:52 UTC 2021 , Edited by admin on Sat Jun 26 13:44:52 UTC 2021
PRIMARY
ChEMBL
CHEMBL1201891
Created by admin on Sat Jun 26 13:44:52 UTC 2021 , Edited by admin on Sat Jun 26 13:44:52 UTC 2021
PRIMARY
INN
4323
Created by admin on Sat Jun 26 13:44:52 UTC 2021 , Edited by admin on Sat Jun 26 13:44:52 UTC 2021
PRIMARY
CAS
14484-47-0
Created by admin on Sat Jun 26 13:44:52 UTC 2021 , Edited by admin on Sat Jun 26 13:44:52 UTC 2021
PRIMARY
RXCUI
22396
Created by admin on Sat Jun 26 13:44:52 UTC 2021 , Edited by admin on Sat Jun 26 13:44:52 UTC 2021
PRIMARY RxNorm
NCI_THESAURUS
C87230
Created by admin on Sat Jun 26 13:44:52 UTC 2021 , Edited by admin on Sat Jun 26 13:44:52 UTC 2021
PRIMARY
DRUG CENTRAL
793
Created by admin on Sat Jun 26 13:44:52 UTC 2021 , Edited by admin on Sat Jun 26 13:44:52 UTC 2021
PRIMARY
PUBCHEM
189821
Created by admin on Sat Jun 26 13:44:52 UTC 2021 , Edited by admin on Sat Jun 26 13:44:52 UTC 2021
PRIMARY
EVMPD
SUB06943MIG
Created by admin on Sat Jun 26 13:44:52 UTC 2021 , Edited by admin on Sat Jun 26 13:44:52 UTC 2021
PRIMARY
MESH
C021988
Created by admin on Sat Jun 26 13:44:52 UTC 2021 , Edited by admin on Sat Jun 26 13:44:52 UTC 2021
PRIMARY
Related Record Type Details
BINDER->LIGAND
BINDING
TRANSPORTER -> SUBSTRATE
TARGET -> INHIBITOR
METABOLIC ENZYME -> INHIBITOR
- Co-administration of deflazacort with clarithromycin, a strong CYP3A4 inhibitor, increased total exposure to 21-desDFZ by about 3-fold. - Co-administration of deflazacort with rifampin, a strong CYP3A4 inducer, significantly decreased the exposure of 21-desDFZ.
Related Record Type Details
METABOLITE ACTIVE -> PRODRUG
METABOLITE INACTIVE -> PARENT
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Tmax PHARMACOKINETIC ORAL ADMINISTRATION

Biological Half-life PHARMACOKINETIC